News

WuXi News

Filter By

2019/03/05

The First WuXi Healthcare Forum opens in Shanghai

Shanghai March 5, 2019 - The first “WuXi Healthcare Forum” opened at the St. Regis Shanghai Jing’an today, gathering together world-class scientists, alongside innovators, entrepreneurs, and investors. The forum attracts application of more than 5,000 industry leaders from 2,000 enterprises and organizations, spanning 20 countries, bring their collective insights to bare on the global challenges facing healthcare – exploring what breakthroughs have been achieved, the present realities and future possibilities.

Read more

2019/02/19

WuXi STA and BioLingus sign exclusive technology and marketing collaboration for sublingual delivery

SHANGHAI and SAN DIEGO, February 19, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec – and BioLingus, a Swiss biotech company, announce they have formed an exclusive technology and marketing collaboration for sublingual delivery.

Read more

2018/12/13

WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange

HONG KONG and SHANGHAI, December 13, 2018-- WuXi AppTec Co., Ltd. (“WuXi AppTec” or “the Company”; Stock code: 603259.SH/2359.HK) today announced the listing of approximately 116 million H-shares on the Main Board of the Hong Kong Stock Exchange. Based on the offer price of HK$68 per share, the net proceeds to be received by the Company are about HK$7,553 million (assuming the Over-allotment Option is not exercised).

Read more

2018/12/11

WuXi AppTec Expands Site in California for Pharmaceutical R&D Services

SAN DIEGO, CA and SHANGHAI, December 11, 2018 – WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces the expansion of its facilities in San Diego, California.

Read more

2018/11/28

WuXi AppTec Receives 2018 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award from Frost & Sullivan

SHANGHAI, Nov. 28, 2018 -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it received the 2018 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award from Frost & Sullivan, a top-notch business research and consulting firm. WuXi was awarded for the second consecutive year.

Read more